At PredictCan Biotechnologies, we are motivated by our objective of giving to each individual the highest chance to fight against cancer. Thusly we develop innovative solutions for earlier cancer detection into conventional health care and cutting-edge models to support pharmaceutical companies to advance personalized drug development program.
we provide the best research
Cancer is a stealth disease that is often detected late, only when physical symptoms appear, making that therapeutic options are diminished. At PredictCan Biotechnologies, we challenge this issue with an innovative blood testing technique that amplifies ultralow precancerous signals for earlier cancer detection.
Our company is developing CanSee, an ultra-sensitive blood-based test for earlier cancer detection. This is an affordable and easy-to-use assay that could be utilized into routine medical care for patients at high risk for cancer development as well as for recurrence monitoring of patients subsequently to tumor resection.
Cancer is a global health issue that urgently needs innovative solutions. Precision medicine in cancer can help to make more accurate and early diagnosis improving treatment outcomes. At PredictCan Biotechnologies, we feel that we could be part of that crusade with our original strategy developing diagnostic tools for earlier detection for each type of cancer.
In precision medicine, the strategy of individualized treatment protocol is an ultimate goal to enhance the therapeutic efficacy and to minimize adverse effects. At PredictCan Biotechnologies, we support this approach by developing tailored 3D models based on our cell reprogramming technology, that reproduce pathological features of tumor cells from different grades and stages of tumors in individual patients.
Our company is developing GenuineSelect, an affordable and high efficacy 3D patient-derived system for high-throughput screening of new active compounds or for drug repositioning, at the population level before moving into conventional clinical trials. Indeed, our system is capable to reproduce in vitro cohorts of patients or of healthy individuals for clinical trial in a dish, a revolutionary strategy for drug development. Moreover, as GenuineSelect mimics pathological features of tumor cells for each patient, it opens the door to personalized medicine in oncology. The high adaptability of our GenuineSelect system authorizes its usage in a large number of cancer types including pancreas, gut, and many more.
In drug development, the ability to challenge the therapeutic value of new molecules on models that mimic global population is a considerable advantage for a better selection before initiating conventional clinical trials. Because differences in drug response are found among different ethnic groups, at PredictCan Biotechnologies we feel that including models derived from diverse ethnic population would add major benefits to preclinical drug selection procedures. The flexibility of our GenuineSelect system allows to generate on-demand cohorts of patients that include ethnic diversity authorizing pharmacoethnicity, an important factor in cancer therapeutics.